COLORADO STATE UNIVERSITY

OS Therapies Advances OST-HER2 Towards FDA Submission with Manufacturing Agreements

5 months ago

• OS Therapies has initiated commercial manufacturing for OST-HER2, an immunotherapy targeting HER2, in preparation for a BLA submission to the FDA. • The company completed a Phase 2b trial of OST-HER2 for recurrent lung metastatic osteosarcoma, with positive results reported in early 2025. • OS Therapies anticipates a Type B or Type C meeting with the FDA before submitting the BLA for accelerated or conditional approval. • A patent notice of allowance from the USPTO provides market exclusivity for OST-HER2 commercial drug product into 2040.

Acuitive Technologies' CITREPORE Receives FDA Clearance as Novel Bone Void Filler

6 months ago

• Acuitive Technologies secured FDA 510(k) clearance for CITREPORE, a synthetic bioactive bone void filler utilizing CITREGEN® technology, designed for orthopedic procedures. • CITREPORE is engineered to resorb predictably, facilitating bone regeneration by releasing citrate, which enhances bone metabolism and formation during the healing process. • The unique bone void filler features over 80% porosity, enabling high fluid absorption, and is available in various shapes and sizes for versatile surgical applications. • Research indicates that citrate stimulates stem cells, promoting osteoinduction, osteoconduction, and extracellular matrix production, enhancing the bone healing process.

AVMA Veterinary Clinical Trials Registry Highlights New Studies in Canine and Feline Oncology and Neurological Disorders

8 months ago

• The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners. • North Carolina State University is exploring a novel treatment approach for oral cancer in cats. • Several studies are investigating canine cancers, including hemangiosarcoma, osteosarcoma, and mast cell tumors, with innovative therapies. • Research is underway to assess treatments for canine cognitive dysfunction and degenerative myelopathy, mirroring human neurological conditions.

Horsemanship Program Eases PTSD Symptoms in Combat Veterans

8 months ago

• A recent study reveals that combat veterans participating in an eight-week horsemanship program experienced a reduction in PTSD symptoms and improved mental well-being. • The program involved veterans learning basic horse safety and behavior, grooming horses, and leading them, promoting present-moment focus and reducing hypervigilance. • Researchers observed decreased stress hormone concentrations in veterans and preliminary evidence of co-regulation between veterans and horses. • Alternative therapies like horsemanship are valuable due to high dropout rates from traditional PTSD treatments among military veterans.

Novel Drug Combination Shows Promise in Reversing Cognitive Decline in Alzheimer's Mouse Model

8 months ago

• A new drug combination targeting neuroinflammation has shown potential in improving memory skills in mice with cognitive issues, including Alzheimer's disease. • The treatment, developed through a partnership between Colorado State University and Sachi Bio, targets two brain proteins critical in neuroinflammation. • Researchers observed that the drug cocktail could potentially reverse cognitive decline, offering a novel approach to treating Alzheimer's and improving memory in aging adults. • Human clinical trials are anticipated to commence next year, with hopes of providing more treatment options earlier in the course of the disease.